Price Target Update on Medtronic plc (NYSE:MDT)

Medtronic plc (NYSE:MDT) : The most positive equity analysts on Medtronic plc (NYSE:MDT) expects the shares to touch $98, whereas, the least positive believes that the stock will trade at $56 in the short term. The company is covered by 14 Wall Street Brokerage Firms. The average price target for shares are $88.11 with an expected fluctuation of $10.8 from the mean.

Other Equity analysts have also commented on the company shares. Major Brokerage house, SunTrust Robinson Humphrey maintains its ratings on Medtronic plc (NYSE:MDT). In the latest research report, SunTrust Robinson Humphrey raises the target price from $93 per share to $98 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on June 13, 2016.

Medtronic plc (NYSE:MDT): stock turned positive on Thursday. Though the stock opened at $85.1, the bulls momentum made the stock top out at $85.77 level for the day. The stock recorded a low of $84.65 and closed the trading day at $85.77, in the green by 1.79%. The total traded volume for the day was 5,672,501. The stock had closed at $84.26 in the previous days trading.

The company shares have rallied 11.63% from its 1 Year high price. On Jun 13, 2016, the shares registered one year high at $86.31 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $82.27 and the 200 Day Moving Average price is recorded at $77.78. On the companys insider trading activities,The officer (SrVP & Chief Scien, Clin, Reg) of Medtronic Plc, Kuntz Richard sold 49,905 shares at $82.6 on June 3, 2016. The Insider selling transaction had a total value worth of $4,122,153. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. Medtronic, Inc. is a subsidiary of the Company.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.